Power in the Combination. Engineered for Synergy. Designed for Results.

EPIK Biosciences is a psychedelic medicine company developing a proprietary platform rooted in NMDA receptor modulation – engineering ketamine-based, synergistic co-delivery formulations targeting mental health disorders, addiction, substance use disorders, and severe chronic pain.

About EPIK

A Short Overview

EPIK Biosciences is a psychedelic medicine company. We are building a proprietary platform of ketamine-based, co-delivery medicines — engineered to deliver powerful therapeutic effects through a combination of active ingredients that work together.

Our medicines target the brain’s own healing mechanisms to treat conditions that have historically been very difficult to treat.

Our approach is different from traditional psychedelic medicine companies because:

  • Our advanced combination formulas are made with compounds that are already FDA approved
  • Most of our delivery formats are designed for home use
  • We believe our approach provides a faster, lower-cost pathway to FDA approval compared to traditional competitors
TREATMENT

Expected Targeted Areas

  • Acute & Chronic Pain

  • Opioid Use Disorder

  • Depression

  • Anxiety Disorders

  • PTSD

LABCORP

LabCorp Partnership

EPIK works with Labcorp, a global life sciences leader, for the development and validation of our formula combinations. Their expertise contributed to over 85% of FDA drug approvals in 2025. This collaboration offers EPIK top-tier testing and regulatory support, enhancing our efficient and economical route to FDA authorization.

Read More
2012 – 2027

Milestone Timeline